CN113347994B - 使用her3抗原结合分子治疗和预防癌症 - Google Patents
使用her3抗原结合分子治疗和预防癌症 Download PDFInfo
- Publication number
- CN113347994B CN113347994B CN202080009114.6A CN202080009114A CN113347994B CN 113347994 B CN113347994 B CN 113347994B CN 202080009114 A CN202080009114 A CN 202080009114A CN 113347994 B CN113347994 B CN 113347994B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- seq
- region
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211117480.0A CN116059347A (zh) | 2019-09-11 | 2020-09-10 | 使用her3抗原结合分子治疗和预防癌症 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1913079.8A GB201913079D0 (en) | 2019-09-11 | 2019-09-11 | Treatment and prevention of cancer using her3 antigen-binding molecules |
| GB1913079.8 | 2019-09-11 | ||
| PCT/EP2020/075319 WO2021048274A1 (en) | 2019-09-11 | 2020-09-10 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211117480.0A Division CN116059347A (zh) | 2019-09-11 | 2020-09-10 | 使用her3抗原结合分子治疗和预防癌症 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113347994A CN113347994A (zh) | 2021-09-03 |
| CN113347994B true CN113347994B (zh) | 2022-09-23 |
Family
ID=68241208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080009114.6A Active CN113347994B (zh) | 2019-09-11 | 2020-09-10 | 使用her3抗原结合分子治疗和预防癌症 |
| CN202211117480.0A Pending CN116059347A (zh) | 2019-09-11 | 2020-09-10 | 使用her3抗原结合分子治疗和预防癌症 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211117480.0A Pending CN116059347A (zh) | 2019-09-11 | 2020-09-10 | 使用her3抗原结合分子治疗和预防癌症 |
Country Status (16)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3023551T3 (en) | 2016-03-25 | 2025-06-02 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| CN109563166B (zh) * | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| AU2018241881B2 (en) | 2017-03-27 | 2024-10-10 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
| CN114790462B (zh) * | 2021-01-25 | 2023-10-31 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向bcma的嵌合抗原受体及其应用 |
| CN112961865B (zh) * | 2021-02-22 | 2023-06-02 | 广西大学 | 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用 |
| WO2022192534A1 (en) * | 2021-03-11 | 2022-09-15 | Elevation Oncology, Inc. | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions |
| TW202313972A (zh) * | 2021-06-03 | 2023-04-01 | 荷蘭商美勒斯公司 | 新nrg1融合物、融合接合處及檢測彼等之方法 |
| WO2022255869A2 (en) * | 2021-06-03 | 2022-12-08 | Merus N.V. | Liquid biopsy assays for detecting nrg1 fusion polynucleotides |
| GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
| JP2024529141A (ja) | 2021-08-13 | 2024-08-01 | ハミングバード・バイオサイエンス・プライベート・リミテッド | Her3抗原結合性分子を使用したがんの処置および予防 |
| CN118541395A (zh) * | 2021-09-03 | 2024-08-23 | 癌症研究科技有限公司 | 用her3抗原结合分子治疗和预防癌症 |
| CN116333118B (zh) * | 2021-12-16 | 2024-04-19 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| IL315262A (en) * | 2022-03-03 | 2024-10-01 | Pfizer | Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| WO2024121226A1 (en) | 2022-12-07 | 2024-06-13 | Hummingbird Bioscience Pte. Ltd. | Combination for treatment and prevention of cancer |
| CN120857946A (zh) | 2023-01-03 | 2025-10-28 | 蜂鸟生物科技私人有限公司 | Her3结合抗体-药物缀合物 |
| KR20260026009A (ko) | 2023-04-06 | 2026-02-25 | 허밍버드 바이오사이언스 피티이. 엘티디. | Her3 항원 결합 분자를 이용한 암의 치료 및 예방 |
| KR20260022498A (ko) | 2023-04-14 | 2026-02-19 | 허밍버드 바이오사이언스 피티이. 엘티디. | 암의 치료 및 예방을 위한 조합물 |
| WO2025057173A2 (en) * | 2023-09-14 | 2025-03-20 | B.G. Negev Technologies And Applications Ltd. | Ligand-based chimeric antigen receptors and uses thereof |
| CN122206706A (zh) | 2023-09-15 | 2026-06-12 | 蜂鸟生物科技私人有限公司 | 使用her3结合分子治疗和预防癌症 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| KR20150036824A (ko) * | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| EP2788382A2 (en) | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| WO2013148315A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US10239951B2 (en) * | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| US20160319253A1 (en) | 2013-12-19 | 2016-11-03 | National Cancer Center | Novel fusion genes as factors responsible for gastric cancer |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | NRG1融合遺伝子を有する細胞の処置における使用のためのErbB-2及びErbB3結合二重特異性抗体 |
| CN111527103A (zh) | 2017-09-08 | 2020-08-11 | 科罗拉多大学董事会,法人团体 | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2019
- 2019-09-11 GB GBGB1913079.8A patent/GB201913079D0/en not_active Ceased
-
2020
- 2020-09-10 EP EP21180956.1A patent/EP3943509A1/en active Pending
- 2020-09-10 WO PCT/EP2020/075319 patent/WO2021048274A1/en not_active Ceased
- 2020-09-10 PT PT207805722T patent/PT3818086T/pt unknown
- 2020-09-10 PL PL20780572T patent/PL3818086T3/pl unknown
- 2020-09-10 MX MX2022002977A patent/MX2022002977A/es unknown
- 2020-09-10 ES ES20780572T patent/ES2896921T3/es active Active
- 2020-09-10 EP EP20780572.2A patent/EP3818086B1/en active Active
- 2020-09-10 CA CA3149853A patent/CA3149853A1/en active Pending
- 2020-09-10 KR KR1020227011181A patent/KR20220086554A/ko active Pending
- 2020-09-10 JP JP2022516173A patent/JP7708741B2/ja active Active
- 2020-09-10 CN CN202080009114.6A patent/CN113347994B/zh active Active
- 2020-09-10 TW TW109131184A patent/TWI883044B/zh active
- 2020-09-10 BR BR112022004474A patent/BR112022004474A8/pt unknown
- 2020-09-10 DK DK20780572.2T patent/DK3818086T3/da active
- 2020-09-10 AU AU2020347473A patent/AU2020347473B2/en active Active
- 2020-09-10 CN CN202211117480.0A patent/CN116059347A/zh active Pending
-
2021
- 2021-01-20 US US17/153,705 patent/US11208498B2/en active Active
- 2021-11-24 US US17/535,313 patent/US20220153870A1/en not_active Abandoned
-
2025
- 2025-07-02 JP JP2025112447A patent/JP2025143396A/ja active Pending
- 2025-08-15 US US19/301,118 patent/US20260132219A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3149853A1 (en) | 2021-03-18 |
| US20210155712A1 (en) | 2021-05-27 |
| DK3818086T3 (da) | 2021-10-04 |
| CN116059347A (zh) | 2023-05-05 |
| KR20220086554A (ko) | 2022-06-23 |
| EP3818086B1 (en) | 2021-08-04 |
| GB201913079D0 (en) | 2019-10-23 |
| TWI883044B (zh) | 2025-05-11 |
| US11208498B2 (en) | 2021-12-28 |
| ES2896921T3 (es) | 2022-02-28 |
| AU2020347473B2 (en) | 2026-07-16 |
| AU2020347473A1 (en) | 2022-03-31 |
| PT3818086T (pt) | 2021-10-26 |
| MX2022002977A (es) | 2022-07-12 |
| JP2022548057A (ja) | 2022-11-16 |
| US20220153870A1 (en) | 2022-05-19 |
| EP3943509A1 (en) | 2022-01-26 |
| JP2025143396A (ja) | 2025-10-01 |
| JP7708741B2 (ja) | 2025-07-15 |
| EP3818086A1 (en) | 2021-05-12 |
| BR112022004474A2 (pt) | 2022-06-21 |
| BR112022004474A8 (pt) | 2023-01-17 |
| US20260132219A1 (en) | 2026-05-14 |
| TW202123926A (zh) | 2021-07-01 |
| PL3818086T3 (pl) | 2022-03-14 |
| WO2021048274A1 (en) | 2021-03-18 |
| CN113347994A (zh) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112513095B (zh) | Her3抗原结合分子 | |
| EP3818086B1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| HK40052624B (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| HK40075856A (en) | Her3 antigen-binding molecules | |
| HK40052624A (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| HK40026637B (en) | Her3 antigen-binding molecules | |
| HK40026637A (en) | Her3 antigen-binding molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40052624 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Singapore, Singapore Applicant after: Hummingbird biotechnology Holdings Ltd. Address before: Singapore, Singapore Applicant before: Hummingbird biotechnology Holdings Pte. Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220408 Address after: Singapore, Singapore Applicant after: Hummingbird biotechnology Pte. Ltd. Address before: Singapore, Singapore Applicant before: Hummingbird biotechnology Holdings Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |